- Home
- » Tags
- » Monoclonal antibody
Top View
- Chemical Aspects of Metal Ion Chelation in the Synthesis and Application Antibody-Based Radiotracers
- Design and Production of Bispecific Antibodies
- Itap Managed Care Working Group Task Team 1: Chronic
- INN Working Document 05.179 Update 2011
- Pdfs/EPAR/Remo Review and Guideline for Treatment
- Ramucirumab: a New Therapy for Advanced Gastric Cancer
- Previous Monoclonal Antibodies Policy
- Ramucirumab) Injection, for Intravenous Use Weeks Following a Major Surgical Procedure and Until Adequate Initial U.S
- Bi-Specific and Tri-Specific Antibodies- the Next Big Thing in Solid Tumor Therapeutics Karie Runcie1, Daniel R
- Radiolabeling of an Anti-Carcinoembryonic Antigen Antibody Fab' Fragment (CEA-Scan) with the Positron-Emitting Radionuclide Tc-94M
- A Fully-Human Anti- Angiopoietin-2 (Ang2) Monoclonal Antibody, in Pati
- REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors Kyriakos P
- Humanization of Antibodies Using a Machine Learning Approach on Large-Scale Repertoire Data
- (INN) for Biological and Biotechnological Substances
- UCSF COVID-19 Monoclonal Antibody Use Process Background
- Cancer Imaging with Radiolabeled Antibodies
- Monoclonal Antibody COVID-19 Treatment for Non-Hospitalized
- A Phase 1B/2 Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
- Phase I Trial of Thetrifunctional Anti-HER2 В Anti-CD3 Antibody
- Enhancing the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Through Manipulation of the Tumour Microenvironment
- Is Monoclonal Antibody Therapy Right for Me?
- "Alemtuzumab" in the Treatment of Multiple Sclerosis
- Monoclonal Antibody Production 1999
- WO 2016/073894 Al 12 May 2016 (12.05.2016) W P O P CT
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Development of Therapeutic Antibodies for the Treatment Of
- Bispecific Antibodies Targeting Tumor-Associated Antigens And
- Did You Recently Test Positive for COVID-19? You May Be Eligible for Treatment
- Ramucirumab (Cyramza) National Drug Monograph June 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
- Chapter 2 Technetium in Medicine 2
- Understanding Secondary Antibodies
- A Phase I First-In-Human Study of Enoticumab
- A Phase II and Biomarker Study of Ramucirumab, a Human
- Severe Anaphylaxis on Murine Antibodies in Sulesomab
- Epcam Detection
- Annex I Summary of Product Characteristics
- Monoclonal Antibodies in Gastrointestinal Cancers
- 125486Orig1s000
- Monoclonal Antibodies for the Treatment of Cancer JOSEPH THOMAS PENTO
- A Phase I First-In-Human Study of Enoticumab (REGN421), a Fully-Human Delta-Like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
- PCORI Topic Brief: Comparative Effectiveness of Second-Line
- A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
- Design of in Silico Trifunctional Antibody
- IBA SCINTIMUN V1
- Top Notch Targeting Strategies in Cancer: a Detailed Overview of Recent Insights and Current Perspectives
- Tumor-Targeted Drug Conjugates As an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
- Monoclonal Antibody Treatment for COVID-19
- Annex I Summary of Product Characteristics
- QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
- Monoclonal Antibodies Treatments
- (INN) for Biological and Biotechnological Substances
- Alemtuzumab – Fact Sheet
- 2015 Annual Report 3 Dear Shareholders
- A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
- Antibody-Cytokine Fusion Proteins: Biopharmaceuticals with Immunomodulatory Properties for Cancer Therapy
- Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
- DRUG NAME: Ramucirumab
- Clinical and Technical Considerations for Imaging Colorectal Cancers with Technetium-99M-Labeled Anticea Fab Fragment
- CYRAMZA® Product Monograph Page 1 of 49
- Monoclonal Antibodies in Cancer Therapy
- Annex I Summary of Product Characteristics
- Alemtuzumab (Campath-1H) in the Treatment of Chronic Lymphocytic Leukemia
- An Engineered Tetra-Valent Antibody Fully Activates the Tie2 Receptor With
- Maccampath, INN- Alemtuzumab
- View Annual Report
- Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses
- 1 CURRICULUM VITAE ARMANDO SARDI, M.D., FACS PRESENT POSITION Chief Surgical Oncology Medical Director, Institute for Cancer Ca